No Data
No Data
Bridgebio Pharma Says Committee For Medicinal Products For Human Use (CHMP) Recommends Marketing Authorization In European Union For Acoramidis For The Treatment Of Wild-type Or Variant Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy...
Express News | EMA's Chmp: Adopted Positive Opinion for Beyonttra (Acoramidis)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives Buy Rating Following Attruby's FDA Approval and Strategic Milestones